• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does RevOpsis Retina Deal Change The Bull Case For Glaukos (GKOS)?

    Simply Wall St·10/22/2026 22:38:48
    Listen to the news
    • Glaukos Corporation entered an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104 and up to four additional retinal biologic candidates targeting nAMD, DME, DR, RVO and geographic atrophy.
    • This move pushes Glaukos deeper into retinal disease, expanding beyond glaucoma devices and iDose TR into drug-based therapies that could reshape its long-term R&D and product mix priorities.
    • We will now look at how Glaukos' investment narrative is affected by this retinal biologics push with RevOpsis' RevMod platform.

    Compare Glaukos’ retinal and glaucoma push with a curated field of eye-care players by scanning the 37 healthcare AI stocks already leaning into data-driven treatment and next-generation precision medicine.

    Glaukos Investment Narrative Recap

    To own Glaukos, you need to be on board with a story built around glaucoma procedures becoming more interventional, with iDose TR and the device portfolio driving that shift while newer corneal and retinal projects widen the treatment footprint. In the near term, the operational focus still sits on execution in glaucoma, payer coverage and procedure adoption, rather than on longer dated retinal biologics.

    The fresh Phase 4 iDose TR data in cataract surgery speaks directly to that near term catalyst by reinforcing the product’s clinical profile where a lot of glaucoma patients already sit. The biggest current risk remains execution and reimbursement, including potential pressure on ophthalmic procedure fees and the investment load required to bring multiple platforms to scale.

    The Phase 4 GLK-101-04 readout on iDose TR inside cataract surgery is the update that matters most right now. Investors get a clearer sense of how Glaukos could deepen share within routine surgical workflows, since many OAG and OHT patients have cataracts and may benefit from a combined procedure that targets intraocular pressure over time.

    This matters for catalysts because iDose TR utilization, payer acceptance and physician comfort using it in standard cataract cases can influence near term revenue mix and margin potential. Execution risk sits in turning strong trial data into procedure volume while also funding newer areas like the RevOpsis retinal biologics partnership without stretching operating leverage too far.

    Glaukos' narrative projects US$1.2b revenue and US$132.4 million earnings by 2029. This assumes 24.9% yearly revenue growth and an earnings swing of about US$320.4 million from a current loss of US$188.0 million to the forecast US$132.4 million profit.

    Uncover why Glaukos' fair value indicates an 11% potential upside to its current price, which could narrow quickly.

    NYSE:GKOS 1-Year Stock Price Chart
    NYSE:GKOS 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts already framed Glaukos’ retinal push as a possible extra growth engine, assuming revenue could reach about US$1.5b and earnings about US$228.4 million by 2029. You can find far more cautious views in the same coverage set, so treat this new RevOpsis deal as a prompt to compare multiple narratives.

    Explore 3 other Glaukos fair value estimates, including one that suggests as much as 52% upside from the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Ideas Beyond Glaukos?

    If Glaukos has you rethinking where the next compelling opportunity might come from, broaden your watchlist with a few focused stock sets built around very different strengths.

    • If you want potential value with quality fundamentals, run your eye over a 30 high quality undervalued stocks that combine healthier balance sheets with pricing that may not fully reflect their underlying metrics.
    • For investors who prioritize resilience first, start with a 30 resilient stocks with low risk scores that score well on financial strength and business stability rather than headline excitement.
    • When you are hunting for under-the-radar potential, scan a 20 high quality undiscovered gems that pair strong underlying performance with relatively low market attention.